Explore the vast range of titles available.

Background Youth depression is highly prevalent and is related to impairments in academic, social and behavioural functioning. Evidence-based treatments are available, but many young people do not respond or sufficiently recover with first-line options, and a significant proportion experience relapse. Consequently, there is clear scope to enhance intervention in this critical period of early-onset depression. Memory specificity training (MeST) is a low-intensity intervention for depression that targets reduced specificity when recalling memories of the past, a common cognitive vulnerability in depression. This randomised controlled trial will assess the efficacy of adding a computerised version of MeST (c-MeST) to usual care for youth depression. Methods/design Young people aged 15–25 years with a major depressive episode (MDE) will be recruited and randomised to have immediate access to the seven session online c-MeST program in addition to usual care, or to usual care and wait-list for c-MeST. The primary outcomes will be diagnostic status of an MDE and self-reported depressive symptoms assessed at baseline, 1-, 3- and 6-month intervals. Autobiographical memory specificity and other variables thought to contribute to the maintenance of reduced memory specificity and depression will be assessed as mediators of change. Discussion Online provision of c-MeST provides a simple, low-intensity option for targeting a cognitive vulnerability that predicts the persistence of depressive symptoms. If found to be efficacious as an adjunct to usual care for depressed youth, it could be suitable for broader roll-out, as c-MeST is highly accessible and implementation requires only minimal resources due to the online and automated nature of intervention. Trial registration Australian New Zealand Clinical Trials Registry, ACTRN12619000234112p . Registered on the 18 February 2019. All items from the WHO Trial Registration Data Set can be found within the protocol. Protocol version 1.0

The tAnGo trial was designed to investigate the potential role of gemcitabine when added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer. When this study was developed, gemcitabine had shown significant activity in metastatic breast cancer, and there was evidence of a favourable interaction with paclitaxel. tAnGo was an international, open-label, randomised, phase 3 superiority trial that enrolled women aged 18 years or older with newly diagnosed, early-stage breast cancer who had a definite indication for chemotherapy, any nodal status, any hormone receptor status, Eastern Cooperative Oncology Group performance status of 0–1, and adequate bone marrow, hepatic, and renal function. Women were recruited from 127 clinical centres and hospitals in the UK and Ireland, and randomly assigned (1:1) to one of two treatment regimens: epirubicin, cyclophosphamide, and paclitaxel (four cycles of 90 mg/m2 intravenously administered epirubicin and 600 mg/m2 intravenously administered cyclophosphamide on day 1 every 3 weeks, followed by four cycles of 175 mg/m2 paclitaxel as a 3 h infusion on day 1 every 3 weeks) or epirubicin, cyclophosphamide, and paclitaxel plus gemcitabine (the same chemotherapy regimen as the other group, with the addition of 1250 mg/m2 gemcitabine to the paclitaxel cycles, administered intravenously as a 0·5 h infusion on days 1 and 8 every 3 weeks). Patients were randomly assigned by a central computerised deterministic minimisation procedure, with stratification by country, age, radiotherapy intent, nodal status, and oestrogen receptor and HER-2 status. The primary endpoint was disease-free survival and the trial aimed to detect 5% differences in 5-year disease-free survival between the treatment groups. Recruitment completed in 2004 and this is the final, intention-to-treat analysis. This trial is registered with EudraCT (2004-002927-41), ISRCTN (51146252), and ClinicalTrials.gov (NCT00039546). Between Aug 22, 2001, and Nov 26, 2004, 3152 patients were enrolled and randomly assigned to epirubicin, cyclophosphamide, paclitaxel, and gemcitabine (gemcitabine group; n=1576) or to epirubicin, cyclophosphamide, and paclitaxel (control group; n=1576). 11 patients (six in the gemcitabine group and five in the control group) were ineligible because of pre-existing metastases and were therefore excluded from the analysis. At this protocol-specified final analysis (median follow-up 10 years [IQR 10–10]), 1087 disease-free survival events and 914 deaths had occurred. Disease-free survival did not differ significantly between the treatment groups at 10 years (65% [63–68] in the gemcitabine group vs 65% [62–67] in the control group), and median disease-free survival was not reached (adjusted hazard ratio 0·97 [95% CI 0·86–1·10], p=0·64). Toxicity, dose intensity, and a detailed safety substudy showed both regimens to be safe, deliverable, and tolerable. Grade 3 and 4 toxicities were reported at expected levels in both groups. The most common were neutropenia (527 [34%] of 1565 patients in the gemcitabine group vs 412 [26%] of 1567 in the control group), myalgia and arthralgia (207 [13%] vs 186 [12%]), fatigue (207 [13%] vs 152 [10%]), infection (202 [13%] vs 141 [9%]), vomiting (143 [9%] vs 108 [7%]), and nausea (132 [8%] vs 102 [7%]). The addition of gemcitabine to anthracycline and taxane-based adjuvant chemotherapy at this dose and schedule confers no therapeutic advantage in terms of disease-free survival in early breast cancer, although it can cause increased toxicity. Therefore, gemcitabine has not been added to standard adjuvant chemotherapy in breast cancer for any subgroup. Cancer Research UK core funding for Clinical Trials Unit at the University of Birmingham, Eli Lilly, Bristol-Myers Squibb, and Pfizer.

SummaryPlanar electrochromatography in the reversed-phase mode has been performed in a commercially available development chamber, which requires only small modification for this purpose. This report illustrates that good separation quality and good reproducibility can both be obtained by use of this apparatus. Only short migration distances - less than 4.0 cm - were obtained under the conditions used.

*Received for publication by Carl Murchison of the Editorial Board, August 29, 1929.

*Received for publication by Carl Murchison of the Editorial Board, December 21, 1927.

In quantum physics, measurements can fundamentally yield discrete and random results. Emblematic of this feature is Bohr’s 1913 proposal of quantum jumps between two discrete energy levels of an atom 1 . Experimentally, quantum jumps were first observed in an atomic ion driven by a weak deterministic force while under strong continuous energy measurement 2 – 4 . The times at which the discontinuous jump transitions occur are reputed to be fundamentally unpredictable. Despite the non-deterministic character of quantum physics, is it possible to know if a quantum jump is about to occur? Here we answer this question affirmatively: we experimentally demonstrate that the jump from the ground state to an excited state of a superconducting artificial three-level atom can be tracked as it follows a predictable ‘flight’, by monitoring the population of an auxiliary energy level coupled to the ground state. The experimental results demonstrate that the evolution of each completed jump is continuous, coherent and deterministic. We exploit these features, using real-time monitoring and feedback, to catch and reverse quantum jumps mid-flight—thus deterministically preventing their completion. Our findings, which agree with theoretical predictions essentially without adjustable parameters, support the modern quantum trajectory theory 5 – 9 and should provide new ground for the exploration of real-time intervention techniques in the control of quantum systems, such as the early detection of error syndromes in quantum error correction. Experiment overturns Bohr’s view of quantum jumps, demonstrating that they possess a degree of predictability and when completed are continuous, coherent and even deterministic.

The online coupled Weather Research and Forecasting-Chemistry (WRF-Chem) model was applied to simulate a haze event that happened in January 2010 in the North China Plain (NCP), and was validated against various types of measurements. The evaluations indicate that WRF-Chem provides reliable simulations for the 2010 haze event in the NCP. This haze event was mainly caused by high emissions of air pollutants in the NCP and stable weather conditions in winter. Secondary inorganic aerosols also played an important role and cloud chemistry had important contributions. Air pollutants outside Beijing contributed about 64.5 % to the PM2.5 levels in Beijing during this haze event, and most of them are from south Hebei, Tianjin city, Shandong and Henan provinces. In addition, aerosol feedback has important impacts on surface temperature, relative humidity (RH) and wind speeds, and these meteorological variables affect aerosol distribution and formation in turn. In Shijiazhuang, Planetary Boundary Layer (PBL) decreased about 278.2 m and PM2.5 increased more than 20 µg m−3 due to aerosol feedback. It was also shown that black carbon (BC) absorption has significant impacts on meteorology and air quality changes, indicating more attention should be paid to BC from both air pollution control and climate change perspectives.